Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation
Conditions
Interventions
fludarabine phosphate
melphalan
+7 more
Locations
1
United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Start Date
February 28, 2012
Primary Completion Date
May 28, 2015
Completion Date
August 29, 2019
Last Updated
September 24, 2019
NCT03147612
NCT02159495
NCT02220985
NCT00093470
NCT01904136
NCT01428635
Lead Sponsor
Roswell Park Cancer Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions